Upgrade to Finviz Elite: Get our fastest platform speed, real-time data, and unlimited screening & charting. Start Free Trial

VRXA

Veraxa Biotech AG

2.01

Jul 27 • 3:59 PM ET +0.21 (11.67%)

2.09

Aftermarket • 5:11 PM ET +0.08 (3.98%)

Healthcare Biotechnology Switzerland Micro NASD

Today, 7:06 AMVeraxa Biotech's bispecific ADC VXA-222 hits key milestone in OmniAb deal, moves into next development phase

Held by: ONEQ

Scroll to Statements

Index	-
Market Cap	63.56M
Enterprise Value	63.53M
Income	6.74M
Sales	0.00M
Book/sh	-2.25
Cash/sh	0.00
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	0.00%
Employees	3
IPO	Sep 30, 2024

P/E	9.38
Forward P/E	-
PEG	-
P/S	-
P/B	-
P/C	2118.69
P/FCF	-
EV/EBITDA	-
EV/Sales	-
Quick Ratio	0.00
Current Ratio	0.00
Debt/Eq	-
LT Debt/Eq	-
Option/Short	No / Yes

EPS (ttm)	0.21
EPS next Y	-
EPS next Q	-
EPS this Y	-
EPS next Y	-
EPS next 5Y	-
EPS past 3/5Y	- -
Sales past 3/5Y	- -
EPS Y/Y TTM	2.24%
Sales Y/Y TTM	-
EPS Q/Q	-91.03%
Sales Q/Q	-
Earnings	-
EPS/Sales Surpr.	- -

Insider Own	75.93%
Insider Trans	0.00%
Inst Own	46.18%
Inst Trans	-
ROA	2.52%
ROE	5.72%
ROIC	-
Gross Margin	-
Oper. Margin	-
Profit Margin	-
SMA20	-6.50%
SMA50	-71.64%
SMA200	-80.00%
Trades

Shs Outstand	31.62M
Shs Float	7.61M
Short Float	3.16%
Short Ratio	0.57
Short Interest	0.24M
52W High	27.36 -92.65%
52W Low	1.70 18.24%
Volatility	9.99% 16.25%
ATR (14)	0.92
RSI (14)	37.02
Beta	0.25
Rel Volume	1.95
Avg Volume	420.89K
Volume	818,642

Perf Week	-5.19%
Perf Month	-14.47%
Perf Quarter	-84.54%
Perf Half Y	-81.13%
Perf YTD	-81.16%
Perf Year	-80.65%
Perf 3Y	-
Perf 5Y	-
Perf 10Y	-
Recom	-
Target Price	-
Prev Close	1.80
Price	2.01
Change	11.67%

Today 03:37PM	VERAXA Biotech (VRXA) Advances Bispecific ADC Program Under OmniAb Collaboration (NewMediaWire) +11.67%
07:00AM	VERAXA Biotech Announces Advancement of Novel Bispecific Antibody Drug Conjugate Program VXA-222 from Joint Discovery Collaboration with OmniAb (GlobeNewswire)
Jul-24-26 04:05PM	VERAXA Biotech Shareholders Approve All Proposals at Extraordinary General Meeting, Strengthening Strategic Flexibility for Future Growth (GlobeNewswire)
02:30PM	VERAXA Biotech AG (VRXA) Appoints Christoph Erkel as Chief Scientific Officer (NewMediaWire)
Jul-23-26 02:30PM	VERAXA Biotech (VRXA) Advances BiTAC(R)-TCE Development With Positive Regulatory Feedback From Germany (NewMediaWire) -9.27%
07:00AM	Loading…
07:00AM	VERAXA Biotech Appoints Christoph Erkel as Chief Scientific Officer to Advance BiTAC Technology Platforms and Portfolio (GlobeNewswire)
Jul-20-26 03:30PM	VERAXA Biotech (VRXA) Receives Regulatory Feedback for BiTAC-TCE Cancer Therapy Platform (NewMediaWire)
07:00AM	VERAXA Biotech Announces Regulatory Progress with its BiTAC-TCE Development Plan (GlobeNewswire)
Jul-15-26 02:40PM	Why VERAXA Biotech (VRXA) Could Benefit More Than Others From AI's Growing Impact on Drug R&D (NewMediaWire)
Jul-13-26 03:30PM	VERAXA Biotech (VRXA) Partners With Ardigen to Advance AI-Driven Cancer Drug Development (NewMediaWire)
07:00AM	VERAXA Biotech to Launch AI-enabled Drug Discovery Collaboration with Ardigen to Support Growing BiTAC Pipeline (GlobeNewswire)
Jul-10-26 04:05PM	VERAXA Biotech AG Appoints Carl von Halem as Interim Chief Financial Officer and Successor to Torsten Burgermeister (GlobeNewswire) -11.29%
Jul-09-26 02:30PM	VERAXA Biotech (VRXA) Advances Lead BiTAC(R) T-Cell Engager Program With Cell Line Development Partnership (NewMediaWire) -10.14%
Jul-06-26 03:00PM	VERAXA Biotech (VRXA) Highlights BiTAC Pipeline Progress, Advances Partnering Strategy (NewMediaWire) +7.35%
12:00PM	The Cancer Therapy Strategy VERAXA Is Betting the Company On (Exec Edge)
07:00AM	Loading…
07:00AM	VERAXA Biotech Provides Business Update and Further Details on Partnering Strategy and Development Timelines (GlobeNewswire)
Jul-02-26 06:40PM	VERAXA Biotech Stock in Focus as Lead Cancer Program Reaches Development Milestone (Exec Edge) +18.26%
03:30PM	VERAXA Biotech (VRXA) Initiates Cell Line Development for Lead BiTAC Cancer Therapy Program (NewMediaWire)
07:00AM	VERAXA Biotech Initiates Cell Line Development with ATUM to Advance its Lead BiTAC-TCE Program (GlobeNewswire)
Jul-01-26 03:45PM	Why VERAXA Biotech (VRXA) Shareholders Should Pay Serious Attention to Antibody Therapeutics Sector Deals (NewMediaWire) -8.24%
Jun-25-26 03:04PM	VERAXA Biotech (VRXA) Advances BiTAC-ADC Platform as It Expands Next-Generation Cancer Therapy Pipeline (NewMediaWire)
Jun-24-26 02:30PM	VERAXA Biotech (VRXA) Expands Heidelberg R&D Facilities To Support Drug Development Pipeline (NewMediaWire) -20.96%
02:15PM	VERAXA Biotech Expands R&D Hub in Heidelberg as Programs Advance Towards Clinical Development (Exec Edge)
07:00AM	VERAXA Biotech Expands R&D Hub in Heidelberg as Innovative BiTAC-TCE and ADC Programs Advance Towards Clinical Development (GlobeNewswire)
Jun-22-26 02:30PM	VERAXA Biotech (VRXA) Showcases BiTAC Cancer Platforms Ahead of BIO International Convention (NewMediaWire) -7.59%
Jun-19-26 10:56AM	VERAXA Biotech (VRXA) Reports Proof-of-Concept Data for BiTAC-ADC Cancer Therapy Platform (NewMediaWire)
Jun-18-26 10:34AM	VERAXA Unveils Cancer Therapy Platform, Sparks Partnering Talks at BIO 2026 (Exec Edge) -23.55%
07:00AM	VERAXA Biotech Establishes in vitro Proof-of-Concept for Novel BiTAC-ADC Technology Platform and Launches Partnering Discussions at BIO International Convention 2026 (GlobeNewswire)
Jun-17-26 03:30PM	Why VERAXA Biotech AG (VRXA) Is 'One to Watch' (NewMediaWire) -38.05%
Jun-12-26 03:00PM	VERAXA Biotech (VRXA) Is 'One to Watch' (NewMediaWire) -19.32%
03:30PM	Loading…
Jun-11-26 03:30PM	VERAXA Biotech (VRXA) Completes Business Combination, Begins Trading on Nasdaq (NewMediaWire) +44.85%

Veraxa Biotech Holding AG engages in operating an oncology-focused biotechnology company, which is the Veraxa Biotech AG (Company). The Company focuses on the development of novel antibody-based drug platforms for the treatment of cancer. The company was founded on June 25, 2025 and is headquartered in Zurich, Switzerland.

Co-FounderDr. Christoph Antz Ph.D.

Ph.D.Dr. Heinz Schwer M.B.A.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

VRXA

Veraxa Biotech AG

Upgrade your Finviz experience